Carlos David Esteban Nieto
Plus aucun poste en cours
Profil
Carlos David Esteban Nieto worked as an Investment Director at Caixa Capital Risc SGEIC SA from 2016 to 2018.
He also worked as a Director at ProRetina Therapeutics SL, Omnia Molecular SL, Sagetis Biotech SL, iMiCROQ SL, and Minoryx Therapeutics SL.
Dr. Esteban Nieto holds an MBA from Imperial College London and a doctorate from the University of Valencia.
Anciens postes connus de Carlos David Esteban Nieto
| Sociétés | Poste | Fin |
|---|---|---|
Sagetis Biotech SL
 Sagetis Biotech SL BiotechnologyHealth Technology Sagetis Biotech SL designs and develops drug-delivery technologies. Its polymeric-based platforms are designed to address areas such as" delivery through the blood-brain barrier, genetic material transfection, and tissue regeneration. The company was founded by David Horna, Eduard Diviu Terradas and Salvador Borros Gomez on April 14, 2010, and is headquartered in Barcelona, Spain. | Directeur/Membre du Conseil | 01/08/2018 |
Caixa Capital Risc SGEIC SA
 Caixa Capital Risc SGEIC SA Investment ManagersFinance Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital armof Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid. | Analyste en capital-investissement | 01/03/2016 |
Omnia Molecular SL
 Omnia Molecular SL Pharmaceuticals: MajorHealth Technology Omnia Molecular SL engaged in the designing of anti-infective pharmaceuticals. The firm used its proprietary platform to synthesize and develop novel drugs targeted at infections such as mycosis and tuberculosis. The company was founded by Lluís Ribas de Pouplana and Juan Gargallo Costa in 2005 and was headquartered in Barcelona, Spain. | Directeur/Membre du Conseil | - |
ProRetina Therapeutics SL
 ProRetina Therapeutics SL BiotechnologyHealth Technology ProRetina Therapeutics SL develops drugs for the treatment of retinal conditions. Its pipeline includes PRO-001 used for the treatment of retinitis pigmentosa and PRO-015 is a gene vector that codes the human proinsulin gene indicated for Retinitis Pigmentosa. The company was founded by Stuart Medina in 2007 and is headquartered in Noain, Spain. | Directeur/Membre du Conseil | - |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Directeur/Membre du Conseil | - |
Formation de Carlos David Esteban Nieto
| Imperial College London | Masters Business Admin |
| University of Valencia | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
iMiCROQ SL
 iMiCROQ SL Medical SpecialtiesHealth Technology iMiCROQ SL develops pathogen detection systems for the food safety industry. Its diagnostic systems test for the presence of listeria, staphylococcus, salmonella, and airborne contaminants. The company was founded by Carlos Arias, Viviana Duarte, Diego Bejarano, Pablo Lozano, and Ioanis Katakis on April 23, 2010, and is headquartered in Tarragona, Spain. | Health Technology |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Health Technology |
Sagetis Biotech SL
Sagetis Biotech SL BiotechnologyHealth Technology Sagetis Biotech SL designs and develops drug-delivery technologies. Its polymeric-based platforms are designed to address areas such as" delivery through the blood-brain barrier, genetic material transfection, and tissue regeneration. The company was founded by David Horna, Eduard Diviu Terradas and Salvador Borros Gomez on April 14, 2010, and is headquartered in Barcelona, Spain. | Health Technology |
ProRetina Therapeutics SL
ProRetina Therapeutics SL BiotechnologyHealth Technology ProRetina Therapeutics SL develops drugs for the treatment of retinal conditions. Its pipeline includes PRO-001 used for the treatment of retinitis pigmentosa and PRO-015 is a gene vector that codes the human proinsulin gene indicated for Retinitis Pigmentosa. The company was founded by Stuart Medina in 2007 and is headquartered in Noain, Spain. | Health Technology |
Omnia Molecular SL
Omnia Molecular SL Pharmaceuticals: MajorHealth Technology Omnia Molecular SL engaged in the designing of anti-infective pharmaceuticals. The firm used its proprietary platform to synthesize and develop novel drugs targeted at infections such as mycosis and tuberculosis. The company was founded by Lluís Ribas de Pouplana and Juan Gargallo Costa in 2005 and was headquartered in Barcelona, Spain. | Health Technology |
Caixa Capital Risc SGEIC SA
Caixa Capital Risc SGEIC SA Investment ManagersFinance Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital armof Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid. | Finance |
